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Gene therapies that chronically suppress vascular endothelial growth factor (VEGF) represent a new 38 
approach for managing retinal vascular leakage and neovascularization. However, constitutive 39 
suppression of VEGF in the eye may have deleterious side effects. Here, we developed a novel strategy 40 
to introduce Flt23k, an intraceptor that binds intracellular VEGF, fused to the destabilizing domain 41 
(DD) of Escherichia coli dihydrofolate reductase (DHFR) into the retina. The expressed DHFR(DD)-42 
Flt23k fusion protein is degraded unless “switched on” by administering a stabilizer; in this case, the 43 
antibiotic trimethoprim (TMP). Cells transfected with the DHFR(DD)-Flt23k construct expressed the 44 
fusion protein at levels correlated with the TMP dose. Stabilization of the DHFR(DD)-Flt23k fusion 45 
protein by TMP was able to inhibit intracellular VEGF in hypoxic cells. Intravitreal injection of self-46 
complementary adeno-associated viral vector (scAAV)-DHFR(DD)-Flt23k and subsequent 47 
administration of TMP resulted in tunable suppression of ischemia-induced retinal neovascularization 48 
in a rat model of oxygen-induced retinopathy (OIR). Hence, our study suggests a promising novel 49 




Retinal neovascularization is a key pathological feature of several leading causes of vision loss, 52 
including diabetic retinopathy, retinopathy of prematurity, and retinal vein occlusions[1]. In these 53 
diseases, abnormally high levels of vascular endothelial growth factor (VEGF) have been observed in 54 
the retina. Excessively high levels of VEGF cause pathological vascular leakage and the formation of 55 
new blood vessels in the retina, which can lead to vision loss. Intraocular injections of anti-VEGF 56 
agents (such as VEGF-neutralizing proteins) have been shown to reduce blood vessel leakage, 57 
allowing fluid reabsorption and resulting in improved visual acuity[2]. However, as this approach does 58 
not address the cause of VEGF production, leakage and neovascularization will recur when the 59 
vitreous levels of exogenous anti-VEGF proteins drop below therapeutic levels. Thus, current 60 
regimens require frequent (as often as monthly) and prolonged treatment, sometimes for many years, 61 
to maintain visual acuity[3]. Although intraocular delivery of anti-VEGF agents is generally safe, some 62 
of the drugs administered can enter the systemic circulation, where chronically high levels of anti-63 
VEGF proteins can increase the risk of systemic adverse effects[4].     64 
Recently, the utilization of gene therapies with the potential to chronically suppress the 65 
production of VEGF in the retina has been proposed as an attractive way to manage ocular 66 
neovascularization[5,6]. While promising, chronic VEGF suppression may have deleterious side 67 
effects on the retina. As the disease course can fluctuate between periods of relative VEGF inactivity 68 
and high activity in many patients, a gene therapy approach that can accommodate such fluctuations 69 
during the course of disease would potentially be a safer and more effective approach than an approach 70 
with prolonged VEGF suppression. In this study, we created a fusion gene consisting of an intracellular 71 
VEGF-targeting decoy receptor, Flt23k[7], and a protein disruption system (based on the destabilizing 72 
domain (DD) of Escherichia coli dihydrofolate reductase (DHFR); DHFR (DD)-Flt23k)[8,9]. Flt23k 73 
consists of domains 2-3 of VEGF receptor 1 (VEGFR1, the highest-affinity VEGF receptor) coupled 74 
to the C-terminal endoplasmic reticulum (ER) retention signal KDEL, a tetrapeptide (Lys-Asp-Glu-75 
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Leu). Flt23k binds intracellular VEGF and sequesters it in the ER, where VEGF undergoes 76 
proteasomal degradation[10,11]. Without a triggering molecule, the expressed DHFR(DD)-Flt23k 77 
fusion protein becomes unfolded and ubiquitinated and then is rapidly processed by the proteasome, 78 
resulting in degradation of the entire fusion protein[12]. A stabilizing drug such as the antibiotic 79 
trimethoprim (TMP) reliably prevents proteasomal destruction of DHFR(DD)-Flt23k, which then 80 
binds to intracellular VEGF and prevents VEGF secretion (Figure 1a, illustration). In addition, to 81 
achieve long-term and early-onset gene expression, a self-complementary adeno-associated viral 82 
vector (scAAV)[13] was utilized to deliver the DHFR(DD)-Flt23k gene into the back of the eye via a 83 
single intravitreal injection. Our data demonstrated that gene delivery of DHFR(DD)-Flt23k and 84 
subsequent administration of TMP allowed disruption of VEGF levels in vitro. Importantly, we also 85 
showed that this approach resulted in tunable suppression of retinal neovascularization in a rat model 86 




Design and validation of the DHFR-based destabilized domain approach in vitro. 91 
scAAVs encoding enhanced green fluorescent protein (EGFP) (or mCherry), Flt23k, DHFR(DD)-92 
yellow fluorescent protein (YFP) (or DHFR(DD)-mCherry), DHFR(DD)-Flt23k, or Flt23k-93 
DHFR(DD) were designed and constructed for the study (Figure 1b). We first validated whether the 94 
DHFR(DD)-protein destabilizing system could be controlled using the stabilizing ligand TMP in vitro. 95 
Human embryonic kidney 293A (HEK293A) cells were transfected with scAAV plasmid (pscAAV)-96 
mCherry, pscAAV-Flt23k, pscAAV-DHFR(DD)-YFP, pscAAV-DHFR(DD)-Flt23k or pscAAV-97 
Flt23k-DHFR(DD) for 24 hours and then exposed to 10 μM TMP or varying doses of TMP (0, 2, 10, 98 
and 50 μM) for 24 hours. A 42-kDa band for DHFR(DD)-Flt23k or Flt23k-DHFR(DD) or a 25-kDa 99 
Flt23k protein was detectable in pscAAV-DHFR(DD)-Flt23k, pscAAV-Flt23k-DHFR(DD) and 100 
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pscAAV-Flt23k-transfected cells, respectively, by western blotting. Neither protein was found in 101 
pscAAV-DHFR(DD)-YFP- or pscAAV-mCherry-transfected cells (Figure 1c). Compared with the 102 
construct with C-terminal fusion of Flt23k (Flt23k-DHFR(DD): 1.41-fold increase, p<0.05; n=3), the 103 
construct with N-terminal fusion (DHFR(DD)-Flt23k: 2.66-fold increase, p<0.001; n=3) was more 104 
flexibly regulated by TMP, as evidenced by relatively low DHFR(DD)-Flt23k protein levels in the 105 
absence of TMP and high levels following TMP exposure (Figure 1d). Interestingly, we observed a 106 
slight increase in DHFR(DD)-Flt23k expression in pscAAV-DHFR(DD)-Flt23k-transfected cells even 107 
without TMP, indicating that some undegraded proteins remained despite the DHFR(DD)-protein 108 
destabilizing system. 109 
Next, we investigated whether DHFR(DD)-Flt23k is dependent on the TMP dose in vitro. 110 
Compared to no TMP, the addition of 2, 10 or 50 μM TMP to the culture medium resulted in an 111 
increase in cytosolic DHFR(DD)-Flt23k expression (2 μM: 2.12-fold, 10 μM: 3.14-fold, 50 μM: 4.45-112 
fold; p<0.05, n=4) (Figure 1e and 1f). Although DHFR(DD)-Flt23k protein levels rose with 113 
increasing doses of TMP, no significant difference was found between 10 and 50 μM TMP treatment 114 
(p=0.2330). These data suggest that the N-terminal fusion construct DHFR(DD)-Flt23k is more 115 
flexibly regulated and can be dose-dependently stabilized by TMP. 116 
 117 
Stabilization of DHFR(DD)-Flt23k functionally inhibits hypoxia-induced VEGF in vitro. 118 
Next, we considered whether the product resulting from TMP induction of DHFR(DD)-Flt23k was 119 
biologically active by examining its capacity to inhibit hypoxia-induced human VEGF production. 120 
HEK293A cells were transfected with pscAAV-DHFR(DD)-Flt23k for 24 hours and exposed to TMP 121 
at a dose between 0 and 50 μM for 24 hours. The cells were incubated under hypoxic conditions for 122 
24 hours. Cell lysates and conditioned medium were harvested for enzyme-linked immunosorbent 123 
assay (ELISA)-based detection of VEGF. Under the hypoxic conditions, compared to pscAAV-124 
mCherry-transfected cells, the cells transduced with pscAAV-Flt23k (intracellular VEGF: 190 ± 27 125 
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pg/μg, p<0.05, n=6-7; extracellular VEGF: 1156 ± 107 pg/mL, p<0.05, n=7) showed reductions in 126 
both intracellular and extracellular VEGF levels (intracellular VEGF: 315 ± 32 pg/μg; extracellular 127 
VEGF: 1564 ± 102 pg/mL; n=5) (Figure 2a and 2b). Cells transfected with pscAAV-DHFR(DD)-128 
Flt23k showed a significant decrease in the intracellular VEGF concentration, an effect that was 129 
dependent on the dose of TMP (DHFR(DD)-Flt23k: 198 ± 19 pg/μg; DHFR(DD)-Flt23k with 2 μM 130 
TMP: 95 ± 16 pg/μg; DHFR(DD)-Flt23k with 10 μM TMP: 63 ± 13 pg/μg, p<0.05; DHFR(DD)-Flt23k 131 
with 50 μM TMP: 45 ± 14 pg/μg, p<0.01; n=8) (Figure 2a). Similarly, the cells transfected with 132 
pscAAV-DHFR(DD)-Flt23k also showed a significant TMP-dependent decrease in extracellular 133 
VEGF secretion (DHFR(DD)-Flt23k: 1192 ± 79 pg/mL; DHFR(DD)-Flt23k with 2 μM TMP: 828 ± 134 
89 pg/mL; DHFR(DD)-Flt23k with 10 μM TMP: 601 ± 97 pg/mL, p<0.01; DHFR(DD)-Flt23k with 135 
50 μM TMP: 507 ± 92 pg/mL, p<0.001; n=7) (Figure 2b). Together, our in vitro data suggest that 136 
gene delivery of DHFR(DD)-Flt23k can reduce the VEGF protein level in a TMP-controlled manner. 137 
Interestingly, we also found that cells transfected with pscAAV-DHFR(DD)-YFP (intracellular 138 
VEGF: 388 ± 33 pg/μg, n=7; extracellular VEGF: 1544 ± 92 pg/mL, n=8) showed a significant 139 
decrease in intracellular (153 ± 24 pg/μg, p<0.001, n=8) and extracellular (932 ± 113 pg/mL, p<0.01, 140 
n=7) VEGF levels when exposed to 50 μM TMP (Figure 2a). We investigated whether the high dose 141 
of TMP inhibits VEGF expression using quantitative polymerase chain reaction (qPCR). Under 142 
hypoxic conditions, cells were exposed to TMP at a dose between 0.01 and 100 μM, and compared to 143 
no TMP, the high dose of TMP (100 μM) decreased VEGF gene expression (Figure S1a). We then 144 
confirmed that compared to cells not treated with TMP, cells transfected with pscAAV-DHFR(DD)-145 
YFP (fold change in VEGFA mRNA: 8.1 ± 0.7, p<0.05; n=3) or pscAAV-DHFR(DD)-Flt23k (fold 146 
change in VEGFA mRNA: 7.8 ± 0.4, p<0.05; n=3) and then exposed to 50 μM TMP also showed a 147 
decrease in VEGF gene expression (DHFR(DD)-YFP: 17.2 ± 1.9; DHFR(DD)-Flt23k: 15.0 ± 1.6; n=3) 148 
(Figure S1b). Thus, our results indicate that a high dose of TMP (> 10 μM) may also inhibit VEGF 149 




Efficiency of scAAV2-mediated gene delivery and validation of transgene product regulation by 152 
the DHFR(DD)-protein destabilizing system in rat retinas. 153 
The rat OIR model was employed to evaluate the therapeutic potential of drug-tunable Flt23k gene 154 
therapy in retinal neovascularization. We first assessed the effectiveness of scAAV2-mediated gene 155 
delivery in OIR rats. Eleven days after intravitreal injection of scAAV2-EGFP into OIR rats (postnatal 156 
day 18 [P18]), EGFP expression was evident across the whole flat-mount retina (Figure 3a). Retinal 157 
cross-sections also showed that scAAV2 drove strong panretinal expression across all retinal layers 158 
(including the ganglion cell layer, inner nuclear layer and outer nuclear layer), as evidenced by the 159 
presence of EGFP (Figure 3b). Given that retinal glia are a potential cellular source of VEGF, we 160 
further characterized scAAV2-mediated transgene expression in retinal glial cells using colabeling of 161 
glial fibrillary acidic protein (GFAP; a marker of glial cells). We found that scAAV2 was able to drive 162 
gene expression in GFAP-positive retinal glial cells (Figure 3c). 163 
To verify the hypothesis that DHFR(DD) provides control of the expressed fusion protein in 164 
vivo, P7 rat pups were intravitreally injected with scAAV2-DHFR(DD)-YFP and then received an 165 
intraperitoneal injection of 3 μg TMP on P14 and P16. Eyes were harvested on P18 to validate the 166 
expression of DHFR(DD)-YFP (Figure 3d). We found that a few YFP fluorescence-positive cells 167 
were present without TMP treatment but YFP protein levels were significantly elevated after the 168 
stabilization of DHFR(DD)-YFP by systemic injection of TMP (Figures 3e and S2). A similar pattern 169 
indicating a drug-tunable effect was shown in scAAV2-DHFR(DD)-mCherry-treated retinas of OIR 170 
rats (Figure S3). To further verify that the drug-tunable effect of the DHFR(DD)-fusion protein is 171 
mediated through posttranslational regulation, DHFR(DD)-Flt23k mRNA and protein levels in the 172 
retinas of OIR rats were quantified using qPCR and western blotting. DHFR(DD)-Flt23k gene 173 
expression was significantly increased in retinas from scAAV2-DHFR(DD)-Flt23k-injected rats 174 
compared with those from scAAV2-DHFR(DD)-mCherry-injected rats (Figure 3f). No statistically 175 
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significant difference (p=0.8410) in the DHFR(DD)-Flt23k mRNA level was found between scAAV2-176 
DHFR(DD)-Flt23k-injected rats treated with TMP (118.5 ± 36.95-fold; n=3) and those not treated 177 
with TMP (132.7 ± 55.14-fold; n=3). DHFR(DD)-Flt23k proteins were detected only in retinas from 178 
scAAV2-DHFR(DD)-Flt23k/TMP-injected rats; no protein was found in retinas from scAAV2-179 
mCherry/vehicle- or scAAV2-DHFR(DD)-Flt23k/vehicle-injected rats (Figure 3g). These results 180 
demonstrate that scAAV2 can effectively deliver DHFR(DD)-Flt23k to the retina in OIR rats and that 181 
subsequent administration of TMP is able to stabilize the expressed DHFR(DD)-Flt23k protein. 182 
 183 
scAAV2-mediated gene delivery of DHFR(DD)-Flt23k reduces VEGF levels and attenuates 184 
retinal neovascularization in the OIR rat model. 185 
The rat OIR model was applied to evaluate the therapeutic potential of drug-tunable DHFR(DD)-186 
Flt23k gene therapy in retinal neovascularization. P7 pups were intravitreally injected with scAAV2-187 
mCherry, scAAV2-Flt23k, scAAV2-DHFR(DD)-mCherry or scAAV2-DHFR(DD)-Flt23k. On P14 188 
and P16, rats received intraperitoneal injections of TMP. Eyes were then harvested on P18 to evaluate 189 
VEGF expression and pathological blood vessel formation on the surface of the retina (retinal 190 
neovascularization; Figures 4a and S4a). Increased mRNA and protein expression of VEGF was 191 
observed in the retina of OIR rats on P18 (Figure S4b and S4c). Compared with eyes that received 192 
scAAV2-mCherry (VEGF: 39.9 ± 4.1 pg/mL; n=8), those intravitreally injected with scAAV2-Flt23k 193 
(VEGF: 28.5 ± 2.6 pg/mL, p<0.05; n=8) showed a significantly reduced level of VEGF in the retina 194 
(Figure 4b). Surprisingly, we found that VEGF expression was significantly reduced in retinas from 195 
scAAV2-DHFR(DD)-Flt23k/vehicle-injected rats (VEGF: 27.3 ± 1.5 pg/mL, p<0.05; n=8) and 196 
scAAV2-DHFR(DD)-Flt23k/TMP-injected rats (VEGF: 22.9 ± 1.4 pg/mL, p<0.01; n=8) compared 197 
with those from scAAV2-DHFR(DD)-mCherry/vehicle-injected rats (VEGF: 42.3 ± 4.8 pg/mL; n=8) 198 
or scAAV2-DHFR(DD)-mCherry/TMP-injected rats (VEGF: 37.8 ± 3.7 pg/mL; n=8) (Figure 5b). A 199 
slight reduction in the retinal VEGF level was found in scAAV2-DHFR(DD)-Flt23k/TMP-injected 200 
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rats compared to scAAV2-DHFR(DD)-Flt23k/vehicle-injected rats, but this difference did not reach 201 
statistical significance (p=0.0508) (Figure 4b). The results indicate that DHFR(DD)-Flt23k can reduce 202 
VEGF levels in the retina even without TMP administration. 203 
We subsequently evaluated the therapeutic potential of the drug-tunable Flt23k gene delivery 204 
system in retinal neovascularization in vivo. Small tufts of vascular endothelial cells were observable 205 
at the edge of new blood vessel growth adjacent to avascular areas (Figures 4c and S5). Compared 206 
with intravitreal injection of scAAV2-mCherry (neovascular area: 3.23 ± 0.25% [95% confidence 207 
interval (CI): 2.68-3.78]; n=15), intravitreal injection of scAAV2-Flt23k significantly inhibited 208 
neovascularization (neovascular area: 1.57 ± 0.14% [95% CI: 1.28-1.86], p<0.001; n=20) (Figure 4d). 209 
In the drug-tunable system, a significant inhibition of retinal neovascularization was observed between 210 
scAAV2-DHFR(DD)-Flt23k-injected rats treated with TMP (1.28 ± 0.13% [95% CI: 1.02-1.55], 211 
p<0.05; n=20) and those not treated with TMP (1.95 ± 0.12% [95% CI: 1.69-2.20]; n=23) (Figure 4d). 212 
Similarly, there was a significant reduction in the neovascular area (1.28 ± 0.13% [95% CI: 1.02-1.55], 213 
p<0.001; n = 20) in retinas from scAAV2-DHFR(DD)-Flt23k/TMP-injected rats compared with those 214 
from scAAV2-DHFR(DD)-mCherry/TMP-injected rats (neovascular area: 2.94 ± 0.25% [95% CI: 215 
2.40-3.48]; n=17) (Figure 4d). We also found a reduction in the retinal neovascular area in scAAV2-216 
DHFR(DD)-Flt23k/vehicle-injected rats (neovascular area: 1.95 ± 0.12% [95% CI: 1.69-2.20], p<0.01; 217 
n=23) compared with rats injected with scAAV2-DHFR(DD)-mCherry/vehicle (neovascular area: 218 
2.49 ± 0.23% [95% CI: 2.00-2.98]; n=19) (Figure 4d). Moreover, no significant difference in the 219 
avascular area was observed among the 6 groups (Figure 4e). Together, our results demonstrate that 220 
gene delivery of DHFR(DD)-Flt23k by scAAV2 allows controlled suppression of retinal 221 






In the present study, we demonstrate that the DHFR(DD)-protein destabilizing system may be a 226 
promising way to regulate the level of Flt23k in the retina for tailored suppression of retinal 227 
neovascularization. Our in vitro studies showed that fusion of Flt23k to the N terminus of DHFR(DD) 228 
allowed relatively good control of Flt23k expression with TMP. We showed that in a dose-dependent 229 
manner, TMP increased the expression of Flt23k, which was functional with the capacity to attenuate 230 
intracellular and extracellular VEGF levels in cells exposed to hypoxic conditions. Finally, intravitreal 231 
gene delivery of DHFR(DD)-Flt23k by scAAV2 and subsequent administration of TMP provided 232 
evidence for tunable attenuation of ischemia-induced retinal neovascularization in a rat model of OIR. 233 
Rapid advances in gene therapy have brought this approach nearly to clinical use in 234 
ophthalmology. Given that the eye is a particularly favorable organ for gene delivery, ocular use is 235 
likely to be among the most successful applications of this technique. We provided proof-of-principle 236 
evidence that intravitreal injection of scAAV2 under a ubiquitous cytomegalovirus (CMV) promoter 237 
in OIR rats resulted in efficient and high-level transgene expression within a time frame relevant to 238 
the treatment of retinal neovascularization. scAAV2 has been shown to exhibit better transduction 239 
efficiency and faster initiation of gene expression in the retina than conventional single-stranded 240 
AAVs[13,14]. However, the ubiquitous CMV promoter cannot be used to express anti-VEGF 241 
therapeutic genes in specific cell types (i.e., Müller glial cells and photoreceptors) that are the primary 242 
source of VEGF production in proliferative retinopathies. As such, it will be important to develop a 243 
better delivery system with either a cell-specific promoter or an AAV variant that targets desired cell 244 
types. Such refinements will lead to more effective therapies while reducing the potential for adverse 245 
effects. 246 
In this study, we show that using scAAV2 to deliver Flt23k can modify VEGF levels and 247 
reduce retinal neovascularization in OIR rats. A similar therapeutic effect was also observed with 248 
AAV-mediated gene delivery of Flt23k in a murine model of choroidal neovascularization[11]. 249 
However, high-level expression of an anti-VEGF protein such as Flt23k in the retina may have 250 
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unwanted consequences. Strategies are needed to regulate transgene expression through the 251 
incorporation of trigger elements into the expression cassette, which are then modulated by an 252 
exogenous drug[15] or endogenous molecules generated as part of the disease process[16]. Different 253 
from those approaches, a protein-destabilizing system based on E. coli DHFR(DD) was used here. In 254 
this system, the engineered DHFR(DD) is rapidly degraded along with any attached protein. A small-255 
molecule pharmacological chaperone (protein stabilizer) such as TMP, a common antibiotic, allows 256 
newly synthesized DDs to be folded and stabilized at higher steady-state levels within cells, thus 257 
protecting the attached therapeutic protein from degradation[17]. An appealing aspect of this strategy 258 
to stabilize therapeutic proteins is that TMP, which is safe and able to cross the blood-retina barrier, 259 
can be administered orally at a chosen time, such as during an exacerbation of retinal angiogenesis[9]. 260 
Oral or topical administration of TMP reliably prevents proteasomal destruction of DD-fused proteins 261 
(delivered via an AAV) in the rodent retina without impacts on retinal function or structure[11,9]. 262 
Thus, TMP-mediated tunable gene therapy could meet the clinical requirement for a tailored and 263 
sustained therapeutic intervention to treat retinal neovascularization. 264 
Although promising in several regards, the DHFR(DD) destabilizing system requires further 265 
refinement. Specifically, we observed that low protein levels of DHFR(DD)-Flt23k were present in 266 
transfected cells not treated with TMP, suggesting that not all DHFR(DD)-fusion proteins were 267 
degraded. Indeed, a significant reduction in the cytosolic VEGF level was seen in DHFR(DD)-Flt23k-268 
transfected cells and the retina of scAAV2-DHFR(DD)-Flt23k-injected eyes without the addition of 269 
TMP. Additionally, Flt23k is a recombinant construct consisting of domain 2/3 of the VEGFR1 270 
receptor coupled with a C-terminal ER-retention signal sequence (KDEL)[10]. The ER-retention 271 
signal sequence allows newly formed fusion proteins to be retained in the ER[18], thus delaying their 272 
degradation and leading to VEGF binding. However, newly formed fusion proteins may generate a 273 
pull effect between the ER-retention signal and the protein-destabilizing signal of DHFR(DD)-Flt23k, 274 
which may result in a delay in protein degradation, thereby increasing the amount of undegraded 275 
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protein in the cytosol. The undegraded or intermediate DHFR(DD)-Flt23k protein can potentially 276 
neutralize cytosolic VEGF and modulate the angiogenic response even without TMP stabilization. 277 
This might account for our observation that retinal neovascularization was reduced in scAAV2-278 
DHFR(DD)-Flt23k-treated rats compared to those that received scAAV2-DHFR(DD)-mCherry. As 279 
OIR is a relatively acute model of retinal neovascularization with a low level of VEGF upregulation, 280 
a small increase in VEGF suppression can impact neovascularization. Thus, rats receiving scAAV2-281 
DHFR(DD)-Flt23k could express low levels of undegraded or intermediate DHFR(DD)-Flt23k protein, 282 
which could neutralize retinal VEGF over time. A higher protein level of stabilized DHFR(DD)-Flt23k 283 
was observed upon TMP injection on P14 and P16 and led to more effective neutralization and thus a 284 
greater suppressive effect on retinal neovascularization. Therefore, our drug-tunable Flt23k gene 285 
therapy might be improved by removing the ER-retention signal sequence and adjusting the viral dose 286 
to reduce basal VEGF inhibition. Further studies in a clinically relevant model of chronic retinal 287 
neovascularization will further inform differences in the benefits of this tunable system. 288 
A limitation of our work was that the safety of the drug-tunable Flt23k gene therapy in the 289 
retina was not evaluated in our proof-of-concept experiments. However, two recent studies have 290 
reported the safety profile of retinal Flt23k gene therapy and systemic TMP administration in mice. 291 
Zhang et al. reported that subretinal AAV-mediated gene delivery of Flt23k had no impact on retinal 292 
function or morphology for up to 6 months[11]. Datta et al. showed that there was no impact on the 293 
visual function or structure of the mouse retina after 3 months of TMP treatment[9]. Although these 294 
two studies have indicated that these strategies are safe in the retina, it will be important to assess the 295 
safety of both AAV-mediated Flt23k gene delivery and TMP administration before current research 296 
can be clinically translated. Another limitation of the present study was that the treatment was 297 
evaluated with a single dose of TMP (10 mg/kg) over a relatively short period of time in OIR rats. The 298 
TMP dose used in this study (10 mg/kg) was based on published reports[8,9] and is within the 299 
recommended dose for humans (10-15 mg/kg)[19]. As indicated by other reports and our in vitro data, 300 
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the dose of TMP impacts the expression of the stabilized DHFR(DD)-Flt23k protein. Therefore, the 301 
dose and frequency of TMP administration will need to be further optimized to match a drug-tunable 302 
Flt23k gene therapy system to the protracted time course of clinical disease processes. 303 
Consistent with previous studies, this study showed that protein expression was dependent on 304 
the TMP dose. Although maximizing the TMP dose to achieve the optimal therapeutic effect is critical, 305 
the systemic administration of high-dose TMP may also have deleterious effects. Indeed, our in vitro 306 
study showed that a high dose of TMP could also inhibit VEGF mRNA expression (Figure S1). High 307 
doses of TMP can induce cell toxicity[20], thus modifying VEGF mRNA expression under hypoxia 308 
condition. Therefore, administration of high-dose TMP together with DHFR(DD)-Flt23k gene 309 
delivery may act synergistically to suppress VEGF at both the transcriptional level and the 310 
posttranslational level. In addition, prolonged oral TMP administration has been shown to disrupt the 311 
gut microbiome, which can impact the central nervous system[21] and in turn modify the progression 312 
of ocular diseases[22]. Thus, topical administration of TMP via eye drops may be a safer alternative. 313 
One study of the rodent retina demonstrated that topical administration of TMP could reliably and 314 
locally stabilize the expression of proteins fused to DHFR(DD) (delivered via an AAV)[9]. Moreover, 315 
to further mitigate systemic adverse events, a TMP-based nonantibiotic small molecule has been 316 
developed to control DHFR(DD)-fused proteins[23]. Therefore, a combination of nonantibiotic eye 317 
drops and tunable Flt23k gene therapy would be a safe and attractive approach for the treatment of 318 
retinal neovascularization. 319 
In summary, our data suggest that the DHFR(DD)-protein destabilizing system is a promising 320 
way to regulate the level of Flt23k in the retina and provides the potential to tailor suppression of 321 
retinal neovascularization. Although further investigations are required to assess long-term safety and 322 
efficacy in clinically relevant models, we believe that this comprehensive strategy has the potential as 323 






Materials and Methods 328 
The sources of the materials and equipment used in this study are listed in Table S1. 329 
 330 
Cell culture. HEK293A (catalog no. R70507; Life Technologies Australia, Mulgrave, VIC, Australia) 331 
and HEK293D (a gift from Dr. Ian Alexander at the Children’s Medical Research Institute, University 332 
of Sydney, Australia) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; catalog 333 
no. 11965092; Life Technologies Australia) supplemented with 10% fetal bovine serum (catalog no. 334 
F9423; Sigma-Aldrich, St. Louis, MO, USA), 50 U/mL penicillin-streptomycin (catalog no. 15070-335 
063; Life Technologies Australia) and 2 mM glutamine (catalog no. 2503008; Life Technologies 336 
Australia). Cell lines were confirmed to be free of mycoplasma using the MycoAlert™ Mycoplasma 337 
Detection Kit (catalog no. LT07; Lonza, Walkersville, MD, USA) and cultured in a humidified 5% 338 
CO2 atmosphere at 37 °C. 339 
 340 
Transfection. Plasmid transfection was performed with Lipofectamine 2000 (catalog no. 11668019; 341 
Life Technologies Australia). In brief, HEK293A cells were plated in a 6-well plate on day 0 342 
(2.5x105/well) and transfected with 750 ng of plasmid DNA using the protocol provided in the kit. 343 
After 24 hours of incubation, the transfection medium was replaced with fresh medium and treated 344 
with TMP (0, 2, 10, or 50 μM; catalog no. T7883; Sigma-Aldrich). Thereafter, cells were either 345 
exposed to hypoxia (GENbag anaer hypoxia bag, catalog no. 45534; bioMeriux, Marcy-l'Étoile, 346 
France) or kept in normoxia for 24 hours. Cell lysates and conditioned medium were then harvested 347 




AAV construction and virus production. EGFP, mCherry, Flt23k, DHFR(DD)-YFP, DHFR(DD)-350 
mCherry, Flt23k-DHFR(DD) and DHFR(DD)-Flt23k complementary DNA (cDNA) sequences 351 
surrounded by AgeI/NotI cleavage sites were obtained by gene synthesis (GenScript, Piscataway, NJ, 352 
USA) and subcloned into the pHpa-trs-SK-EGFP plasmid (a gift from Dr. Douglas M. McCarty at the 353 
Center for Gene Therapy, Nationwide Children’s Hospital, USA) by replacing the EGFP sequence. 354 
The Flt23k DNA sequence was kindly provided by Dr. Balamurali K Ambati at the Moran Eye Center 355 
(University of Utah, USA). The DHFR(DD) DNA sequence was based on pBMN-DHFR(DD)-YFP 356 
(a gift from Dr. Thomas Wandless at the Stanford University, USA; Addgene plasmid #29325). 357 
Recombinant scAAV2s were packaged as previously described[24]. Briefly, the scAAV2s were 358 
prepared by transfecting HEK293D cells with the targeted plasmids (pscAAV-mCherry, pscAAV-359 
Flt23k, pscAAV-DHFR(DD)-YFP, pscAAV-DHFR(DD)-mCherry, pscAAV-DHFR(DD)-Flt23k or 360 
pHpa-trs-SK-EGFP), a helper plasmid (pXX6, kindly provided by the UNC Vector Core Facility, USA) 361 
and an AAV2 capsid plasmid (pXX2, kindly provided by the UNC Vector Core Facility, USA) using 362 
the calcium phosphate method. Viral vectors were purified using the AAVpro Purification Kit (catalog 363 
no. 6666; Clontech Laboratories, Mountain View, CA, USA), and titers were quantified by qPCR. 364 
 365 
Western blot analysis. Cells or retinas were collected in 150 μL of Pierce RIPA buffer (catalog no. 366 
89900; Life Technologies Australia) with a protease inhibitor cocktail (catalog no. 14692300; Roche 367 
Diagnostics, Basilea, Swiss). The lysates were homogenized using a sonicator for 5-10 seconds and 368 
then centrifuged at full speed for 15 minutes at 4 °C. The supernatants were collected and quantified 369 
using a Pierce™ BCA assay kit (catalog no. 23227; Life Technologies Australia). Proteins were 370 
denatured at 85 °C for 10 minutes, followed by separation on NuPAGE™ Novex™ 4-12% Bis-Tris 371 
Protein Gels (catalog no. NP0321BOX; Life Technologies Australia) using gel electrophoresis and 372 
transfer to polyvinylidene fluoride membranes (catalog no. IPVH00010; Immobilon-P; Merck 373 
Millipore, Burlington, MA, USA) using the XCell II™ Blot Module (Life Technologies Australia) at 374 
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30 volts for 1 hour. The membranes were then blocked with 5% skim milk in TBS-T (10 mM Tris, 375 
150 mM NaCl, and 0.05% Tween-20) at room temperature for 1 hour and incubated with a mouse anti-376 
VEGFR1 antibody (Flt-1/EWC) (1:500 dilution; catalog no. ab9540; Abcam, Cambridge, UK) 377 
overnight at 4 °C or with a mouse anti-GAPDH antibody (clone 6C5, 1:500 dilution; catalog no. 378 
MAB374; Merck Millipore) or mouse anti-Actin antibody (clone C4, 1:5000 dilution; catalog no. 379 
MAB1501; Merck Millipore) at room temperature for 1 hour. The membranes were washed and further 380 
incubated with a goat anti-mouse IgG HRP-conjugated secondary antibody (1:4000 dilution; catalog 381 
no. 12-349; Merck Millipore) at room temperature for 1 hour. The membranes were then developed 382 
using the Amersham ECL Prime Western Blotting Detection Kit (catalog no. RPN2235; GE 383 
Healthcare Australia, Parramatta, NSW, Australia). 384 
 385 
ELISA. The VEGF protein level was detected in HEK293A cell lysates, conditioned media and rat 386 
retinal tissue lysates using ELISA. For cell and tissue lysates, samples were prepared in Pierce RIPA 387 
buffer. Lysates and conditioned media were analyzed using human or rat VEGF ELISA kits (catalog 388 
no. DY293B and RRV00; R&D Systems, Inc., Minneapolis, MN, USA) per the manufacturer’s 389 
instructions, and results were read at a 450-nm wavelength using a CLARIOstar microplate reader 390 
(BMG LABTECH, Ortenberg, Germany). 391 
 392 
qPCR. Total RNA was extracted and purified from cells or retinas using TRIzol Reagent (catalog no. 393 
15596026; Life Technologies Australia) according to the manufacturer’s instructions. cDNA synthesis 394 
from total RNA was achieved using a high-capacity RT kit (catalog no. 4368814; Life Technologies 395 
Australia). Two nanograms of cDNA were used for real-time PCR using an ABI QuantStudio3 device 396 
(Applied Biosystems, Foster City, CA, USA) and TaqMan Fast Master mix (catalog no. 4444557; Life 397 
Technologies Australia) with the TaqMan assay probes for VEGFA (Hs00900054_m1). Human 398 
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HPRT1 (Hs99999909_m1) was used as the reference gene. Transcript levels were calculated using the 399 
ΔΔCt method, as previously described by Livak[25]. 400 
 401 
Animals. Female Sprague-Dawley rats were supplied by the Cambridge Farm Facility of the 402 
University of Tasmania and housed in standard cages with free access to food and water in a 403 
temperature-controlled environment under a 12-h light (50 lux illumination)/12-h dark (< 10 lux 404 
illumination) cycle to minimize possible light-induced eye damage. All animal experiments described 405 
adhered to the guidelines of the Association for Research in Vision and Ophthalmology Statement for 406 
the Use of Animals in Ophthalmic and Vision Research and were approved by the Animal Ethics 407 
Committee of the University of Tasmania, Australia (ethics approval number A0017598). 408 
 409 
Rat model of OIR and vessel quantification. We employed a modified rat OIR protocol based on a 410 
previous study[26]. Briefly, newborn Sprague-Dawley rats and their nursing mothers were housed in 411 
a commercially available chamber (A-Chamber; BioSpherix, Parish, NY, USA) within 12 hours of 412 
birth (P0) and exposed to daily cycles of 80% O2 for 21 hours and room air for 3 hours from P0 to P14. 413 
The pups were then returned to room air until P18. An oxygen controller (ProOx 110; BioSpherix) 414 
was used to monitor and control the oxygen level in the humidified chamber. The rats were sacrificed 415 
on P18, and their retinas were dissected and stained with 5 g/mL Alexa FluorTM 488-conjugated 416 
isolectin B4 (isolectin GS-IB4 from Griffonia simplicifolia; catalog no. I21411; Life Technologies 417 
Australia). The sizes of the neovascularization and vaso-obliteration areas in the rat retinas were 418 
quantified with Adobe Photoshop (CC 2017.1.1) by two blinded assessors (JC and GSL). If the 419 
isolectin GS-IB4-labeled retinal vascular area was < 20% of the total retinal area, the sample was 420 




Intravitreal injection. Intravitreal injections of AAVs were performed under a surgical microscope. 423 
In brief, after making a guide track through the conjunctiva and sclera at the superior temporal 424 
hemisphere behind the limbus using a 30-gauge needle, a hand-pulled glass micropipette connected to 425 
a 10-μL Hamilton syringe (Bio-Strategy, Broadmeadows, VIC, Australia) was inserted into the vitreal 426 
cavity. A total of 1 μL of AAVs (2-2.5x109 viral genomes) was injected into an eye of OIR rats on P7, 427 
and an equal amount of saline was injected into the contralateral eye of the same animal. A total of 428 
192 neonatal rats (from 20 litters) were used in our in vivo study. Animals were randomly allocated 429 
into the following groups: scAAV2-EGFP (n=5), scAAV2-mCherry (n=29), scAAV2-Flt23k (n=30), 430 
scAAV2-DHFR(DD)-YFP (n=10), scAAV2-DHFR(DD)-mCherry (n=52), and scAAV2-DHFR(DD)-431 
Flt23k (n=66). Any issues arising from the injection, including large backflow upon removal of the 432 
needle and the presence of hemorrhaging anywhere on the eye, resulted in exclusion from the study. 433 
 434 
TMP administration. OIR rats were intraperitoneally injected with a TMP lactate salt (catalog no. 435 
T0667; Sigma-Aldrich) or vehicle on P14 and P16. TMP was freshly dissolved in nanopure water and 436 
diluted to a concentration of 30 mg/mL. Rats were given 100 μL of this solution, which equates to 3 437 
mg of TMP/rat/dose. 438 
 439 
Immunofluorescence analysis. Rat pups were euthanized on P18. Eyeballs were removed and fixed 440 
in a 4% formaldehyde solution in PBS for 1 hour at room temperature. The cornea and lens were 441 
removed, and the globes were incubated with 18% sucrose until the eyeball sank to the bottom of the 442 
container at room temperature. The eyes were then placed in 30% sucrose overnight. Samples were 443 
embedded in optimal cutting temperature compound (catalog no. IA018; ProSciTech, Kirwan, QLD, 444 
Australia) and stored at -80 °C. Serial cryosections (20-μm thickness) were obtained and stored at -20 445 
°C. The sections were rinsed in three washes of PBS and then underwent immunofluorescence labeling 446 
with NucBlueTM Live Cell Stain ReadyProbes Reagent (catalog no. R3760S; Life Technologies 447 
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Australia) for 20 minutes and an anti-GFAP antibody (1:500 dilution; catalog no. G3893; Merck 448 
Millipore) for 1 hour. The sections were washed and mounted with Dako fluorescent mounting 449 
medium (catalog no. s3020; DAKO, Carpinteria, CA, USA). Images were digitized using a 450 
fluorescence microscope (Zeiss Axio Imager Microscope; Carl-Zeiss-Strasse, Oberkochen, Germany) 451 
equipped with a charge-coupled digital camera (Axiocam MRm, Zeiss) and image acquisition software 452 
(ZEN2, Zeiss). The entire retina was photographed using appropriate filters to capture the fluorescence 453 
emission spectra of mCherry (610 nm), EGFP/isolectin B4-FITC (509 nm), and NucBlue (460 nm), 454 
and separate images were merged to form a complete image of the retinal section. The fluorescence of 455 
the EGFP-positive area in the total retina was quantified with ImageJ. 456 
 457 
Statistical analysis. Statistical analysis was performed using GraphPad Prism 7 for all experimental 458 
data. Measurement data are presented as the mean ± standard error of the mean (SEM). Comparisons 459 
among multiple groups were analyzed by two-tailed Student’s t-tests, one-way or two-way ANOVA 460 
followed by Tukey’s multiple comparisons. Values were determined to be significant when the p value 461 
was less than 0.05. 462 
  463 
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Figure Captions 489 
 490 
Graphical Abstract. Schematic diagram of the tunable system utilizing the DHFR(DD)-Flt23k 491 
approach to reduce VEGF secretion. (a) The schematic shows normal VEGF secretion. (b) Without 492 
the ligand TMP, the DHFR(DD)-Flt23k protein is destabilized and degraded by the proteasome. (c) In 493 
the presence of the ligand TMP, DHFR(DD)-Flt23k is stabilized and sequestered in the ER, thereby 494 
conditionally inhibiting VEGF. Green lines indicate the intracellular and extracellular distributions of 495 
VEGF. Blue lines indicate proteasomal degradation of the DHFR(DD)-Flt23k protein. Orange lines 496 
indicate the uptake of cell-permeable TMP. TMP, trimethoprim; VEGF, vascular endothelial growth 497 
factor; ER, endoplasmic reticulum. 498 
 499 
Figure 1. Characterization of DHFR(DD)-Flt23k gene transfer in vitro. (a) The schematic 500 
illustrates conditional protein stabilization by the ligand TMP. The DHFR(DD)-fused Flt23k protein 501 
is an unstable cytosolic protein that is rapidly degraded by the proteasome unless protected by the 502 
specific cell-permeable ligand TMP. (b) The schematic shows plasmid constructs. (c and d) Two days 503 
after transfection, the expression of Flt23k or DHFR(DD) fused with Flt23k in HEK293A cells in the 504 
presence of 0 or 10 μM TMP was confirmed by western blotting. The graph shows the quantification 505 
of protein expression. Two-tailed Student’s t-tests were performed to determine the significance of 506 
differences (***p < 0.001, *p < 0.05). (e and f) The DHFR(DD)-Flt23k level in HEK293A cells was 507 
increased by TMP in a dose-dependent manner (0-50 μM). The graph shows the quantification of 508 
protein expression. Two-tailed Student’s t-tests were performed to determine the significance of 509 
differences (**p<0.01; #p<0.05 compared to DHFR(DD)-Flt23k with 0 μM TMP). All data are 510 
presented as the mean ± SEM. Corresponding uncropped images of western blots are shown in Figure 511 
S6. CMV, cytomegalovirus; mCH, mCherry; EGFP, enhanced green fluorescent protein; YFP, yellow 512 
fluorescent protein; TMP, trimethoprim. 513 
 514 
Figure 2. Stabilization of DHFR(DD)-Flt23k inhibits intracellular and extracellular VEGF. Cells 515 
were transfected and treated with different doses of TMP (0, 2, 10, or 50 μM), followed by treatment 516 
with hypoxia for 24 hours. Histograms show that compared to DHFR(DD)-YFP or DHFR(DD)-Flt23k, 517 
stabilized DHFR(DD)-Flt23k inhibits intracellular (a) and extracellular (b) VEGF expression, as 518 
detected by ELISA. One-way ANOVA followed by Tukey’s multiple-comparisons test was performed 519 
to determine the significance of differences (***p<0.001, **p<0.01, *p<0.05). All data are presented 520 
as the mean ± SEM. mCH, mCherry; YFP, yellow fluorescent protein; TMP, trimethoprim. 521 
 522 
Figure 3. scAAV2-mediated gene transduction following intravitreal injection into the retina of 523 
OIR rats. Representative images of retinal flat-mount sections (a) and cross-sections (b and c) from 524 
OIR rats (P18) 11 days after scAAV2-EGFP intravitreal injection. Intact retinas were confirmed with 525 
NucBlue™ (blue) staining. (a) Retinal flat mounts showing EGFP expression distribution (green). 526 
Scale bars: 1 mm. (b) Distribution and colocalization of EGFP (green) and GFAP staining (retinal glial 527 
cell marker, red) in retinal cross-sections. Scale bars: 500 μm. (c) High-magnification view of a retinal 528 
cross-section. Transduction of retinal cells is evident by the presence of EGFP-positive cells in the 529 
outer nuclear layer (arrows) and inner segments. Scale bars: 100 μm. (d) Schematic diagram of the rat 530 
OIR model protocol to illustrate the timing of viral vector injection and intraperitoneal TMP injection. 531 
(e) Retinal flat-mount section showing TMP-mediated YFP protein stabilization in an OIR rat. Scale 532 
bars: 1 mm (left panels) and 70 μm (right panels). (f) DHFR(DD)-Flt23k mRNA expression levels in 533 
retinas injected with scAAV2-DHFR(DD)-mCherry or scAAV2-DHFR(DD)-Flt23k with or without 534 
TMP, as quantified using qPCR (n=3). Two-tailed Student’s t-tests were performed to evaluate 535 
differences between groups. All data are presented as the mean ± SEM. (g) Retinal DHFR(DD)-Flt23k 536 
protein levels determined using western blotting, each with three replicates. Corresponding uncropped 537 
images of western blots are shown in Figure S6. OIR, oxygen-induced retinopathy; EGFP, enhanced 538 
22 
 
green fluorescent protein; GFAP, glial fibrillary acidic protein; mCH, mCherry; YFP, yellow 539 
fluorescent protein; TMP, trimethoprim; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, 540 
outer nuclear layer. 541 
 542 
Figure 4. Effects of intravitreal scAAV2 injection on retinal neovascularization in the rat OIR 543 
model. (a) Schematic of the rat OIR model protocol to illustrate the timing of viral vector injection 544 
and intraperitoneal TMP injection. Neonatal rats were exposed to daily cycles of 80% oxygen for 21 545 
hours and room air for 3 hours from P0 to P14 and received an intraperitoneal injection of 3 mg of 546 
TMP on P14 and P16. On P14, the animals were returned to room air until P18. scAAV2-mCherry, 547 
scAAV2-Flt23k, scAAV2-DHFR(DD)-mCherry, or scAAV2-DHFR(DD)-Flt23k was injected on P7. 548 
(b) Rat retinal VEGF levels quantified using ELISA analysis of 8 retinas (3 littermates). One-way 549 
ANOVA followed by Tukey’s multiple comparisons test was performed to determine the significance 550 
of differences (**p<0.01, *p<0.05). (c) A typical cluster of vascular structures represented as 551 
“neovasculature” on a flat-mounted retina harvested on P18 after intravitreal injections on P7 and 552 
stained with isolectin B4. Retinal neovascularization is highlighted in white, and insets show the 553 
selected areas at high magnification. Scale bars: 250 μm. Corresponding uncropped images of retinas 554 
are shown in Figure S5. (d) Retinal neovascular area quantified from 15 to 23 retinas. One-way 555 
ANOVA followed by Tukey’s multiple-comparisons test was performed to compare groups 556 
(***p<0.001, **p<0.01, *p<0.05). (e) Retinal avascular area quantification. Data are presented as the 557 
mean ± SEM from 11 to 22 retinas. No significant difference was observed in the avascular area. All 558 
data are presented as the mean ± SEM. OIR, oxygen-induced retinopathy; mCH, mCherry; TMP, 559 
trimethoprim. 560 
  561 
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Table S1. Key Resources 562 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse anti-VEGF receptor 1 antibody (Flt-1/EWC) Abcam Cat# ab9540 
Mouse anti-GFAP antibody Millipore Cat# G3893 
Mouse anti-GAPDH (clone 6C5) antibody Chemicon Cat# MAB374 
Mouse anti-Actin (clone C4) antibody Millipore Cat# MAB1501 
Goat anti-mouse IgG HRP-conjugated secondary 
antibody Millipore Cat# 12-349 
Isolectin GS-IB4 From Griffonia simplicifolia, 
Alexa Fluor™ 488 Conjugate 
Life Technologies 
Australia Cat# I21411 
NucBlueTM Live Cell Stain ReadyProbes Reagent Life Technologies Australia Cat# R3760S 
Plasmid DNA 
pHpa-trs-SK-EGFP 
Kindly provided by Dr 
Douglas M. McCarty, 






Kindly provided by 




Kindly provided by 




The plasmid was 
generated by Liu Lab 






The plasmid was 
generated by Liu Lab 




The plasmid was 
generated by Liu Lab 




The plasmid was 
generated by Liu Lab 




The plasmid was 
generated by Liu Lab 




The plasmid was 
generated by Liu Lab 




Glutamine  Life Technologies Australia Cat# 2503008 
Penicillin-streptomycin Life Technologies Australia Cat# 15070063 
Trimethoprim Sigma-Aldrich Cat# T7883 
Trimethoprim lactate salt  Sigma-Aldrich Cat# T0667 
Critical Commercial Assays 
MycoAlert™ Mycoplasma Detection Kit Lonza, Walkersville Cat# LT07 
AAVpro Purification Kit Clontech Laboratories Cat# 6666 
Pierce™ BCA assay kit Life Technologies Australia Cat# 23227 
Amersham ECL Prime Western Blotting Detection 
Kit 
GE Healthcare 
Australia Cat# RPN2235 
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DuoSet® Ancillary Reagent Kit 2 R&D Systems Cat# DY008 
Duoset® human ELISA VEGF Kit R&D Systems Cat# DY293B-05 
Rat VEGF Quantikine ELISA Kit R&D Systems Cat# RRV00 
High capacity cDNA reverse transcription Kit Life Technologies Australia Cat# 4368814 
TaqMan Fast Master mix Life Technologies Australia Cat# 4444557 
Experimental Models: Cell Lines 
Human embryonic kidney 293A Life Technologies Australia Cat# R70507 
Human embryonic kidney 293D 
Kindly provided by 
Professor Ian 





Experimental Models: Organisms/Strains 
Sprague-Dawley rat 
Cambridge Farm 
Facility in University 




CLARIOstar microplate reader  BMG LABTECH, Ortenberg n/a 
QuantStudio3 Applied Biosystems n/a 
Oxygen controller, ProOx 110 BioSpherix n/a 
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Hamilton syringe Bio-Strategy  n/a 
Zeiss Axio Imager Microscope Carl-Zeiss-Strasse, Oberkochen, Germany n/a 
qPCR Probes 
Human VEGFA TaqMan probe sequences: N/A Applied Biosystems Hs00900054_m1 
Human HPRT1 TaqMan probe sequences: N/A Applied Biosystems Hs99999909_m1 
Software and Algorithms 
ImageJ version 1.48 Schneider et al., 2012 https://imagej.nih.gov/ij 
Prism 7 GraphPad Software n/a 
Adobe Photoshop (CC 2017.1.1) Connor et al., 2009 Adobe 
Other 
Dulbecco's modified Eagle's medium Life Technologies Australia Cat# 11965092 
Fetal bovine serum Sigma-Aldrich Cat# F9423 
Opti-MEM I reduced serum medium Life Technologies Australia Cat# 31985088 
Lipofectamine 2000 Life Technologies Australia Cat# 11668019 
Hypoxia bag BioMeriux Cat# 45534 
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Anaerotic indicator BioMeriux Cat# 96118 
Pierce RIPA buffer Life Technologies Australia Cat# 89900 
Protease Inhibitor Cocktail Roche Diagnostics Cat# 14692300 
NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels Life Technologies Australia 
Cat# 
NP0321BOX 
Polyvinylidene fluoride membranes Millipore Cat# IPVH00010 
XCell II™ Blot Module Life Technologies Australia Cat# 11965118 
Trizol Reagent Life Technologies Australia Cat# 15596026 
Optimal cutting temperature compound  ProSciTech Cat# IA018 
Dako Fluorescent mounting medium DAKO Cat# S3020 
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